Trial Profile
A Randomized, Double-blind, Placebo-controlled, Multiple Ascending Dose Study to Evaluate the Safety, Tolerability, and Pharmacokinetics of E2006 in Healthy Adult and Elderly Subjects
Status:
Completed
Phase of Trial:
Phase I
Latest Information Update: 02 Feb 2021
Price :
$35
*
At a glance
- Drugs Lemborexant (Primary)
- Indications Insomnia
- Focus Adverse reactions
- 01 Jan 2021 Results assessing potential of lemborexant for residual morning and next-day effects, including somnolence from 9 studies (E2006-A001-001 Part B, E2006-A001-002, E2006-A001-003, E2006-E044-106, E2006-A001-107, E2006-A001-108, E2006-G000-201, E2006-G000-303 & E2006-G000-304) published in the Postgraduate Medicine.
- 01 Jun 2013 Status changed from active, no longer recruiting to completed as reported by ClinicalTrials.gov.
- 25 Apr 2013 Planned End Date changed from 1 May 2013 to 1 Jun 2013 as reported by ClinicalTrials.gov.